Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -2.58%33 EV-to-Revenue is -2.27 as of Aug. 20, 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Standard BioTools ranks better than 99.63% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Standard BioTools's enterprise value is $-191.77 Mil.
Standard BioTools's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $84.60 Mil. Therefore, Standard BioTools's EV-to-Revenue for today is -2.27.
The historical rank and industry rank for Standard BioTools's EV-to-Revenue or its related term are showing as below:
LAB'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.2 Med: 2.97 Max: 6.8
Current: -2.27
During the past 13 years, the highest EV-to-Revenue of Standard BioTools was 6.80. The lowest was -2.20. And the median was 2.97.
LAB's EV-to-Revenue is ranked better than 99.63% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: 3.07
vs LAB: -2.27
Standard BioTools's share price for today is $0.6543.
Standard BioTools's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools EV-to-Revenue Related Terms
Standard BioTools EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Standard BioTools's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Standard BioTools's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools EV-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Standard BioTools's EV-to-Revenue falls into.
Standard BioTools's current Enterprise Value is $-191.77 Mil.
Standard BioTools's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $84.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (LAB) has a EV-to-Revenue of -2.27 as of Aug. 20, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #3 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 0.40000000000001%.
Is Standard BioTools' EV-to-Revenue too high?
Standard BioTools' current EV-to-Revenue is -2.27. Based on the distribution chart, Standard BioTools ranks #3 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' EV-to-Revenue compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #3 out of 813 companies for EV-to-Revenue. This places Standard BioTools in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-Revenue is 3.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Devices & Instruments company?
The median EV-to-Revenue among Medical Devices & Instruments companies is 3.07, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median EV-to-Revenue is 3.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current EV-to-Revenue is -2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 7.8% below its estimated fair value. The current EV-to-Revenue is -2.27. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Standard BioTools (LAB), the current EV-to-Revenue is -2.27 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 7.8% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Fairly Valued.
Key valuation signals for LAB:
EV-to-Revenue: -2.27
GF Value™: $0.71 vs. price of $0.65 (7.8% below fair value)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
